MLLT3 and leukemia: Co-IP showed that the inhibitor 1 dose-dependently reduced MLL-AF9-bound DOT1L and AF4 in Molm-13 leukemia cells (Figure 3A), indicating it is cell-permeable and can disrupt the target PPIs in cells.